EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Erythropoietin induces tumour progression and CD39 expression on immune cells in a preclinical model of triple‐negative breast cancer

Stéphanie Bessoles iD, Andrada Chiron, Guillaume Sarrabayrouse, Pierre De La Grange, Amine M Abina, Salima Hacein-Bey-Abina

Immunology · 2024

DOI: 10.1111/imm.13832 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology, 2024. Verfasst von Stéphanie Bessoles und 5 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, CNRS, INSERM, UTCBS, Unité des Technologies Chimiques et Biologiques pour la Santé, Paris, France. Hauptthemen laut MEDLINE: Antigens, CD, Apyrase, Erythropoietin, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Groupement des Entreprises Françaises dans la lutte contre le Cancer, Ligue Contre le Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The adverse effects observed in some cancer patients treated with erythropoiesis‐stimulating agents such as erythropoietin (EPO) might be due to the latter's well‐known immunosuppressive functions. Here, we used a mouse model of syngeneic triple‐negative breast cancer to explore EPO's immunomodulatory role in a tumour setting. Our results showed that EPO treatment promotes tumour growth, exacerbates the ‘immune desert’, and results in a ‘cold tumour’. EPO treatment changed the immune cell distribution in peripheral blood, secondary lymphoid organs, and the tumour microenvironment (TME). Our in‐depth analysis showed that EPO mainly impacts CD4 T cells by accelerating their activation in the spleen and thus their subsequent exhaustion in the TME. This process is accompanied by a general elevation of CD39 expression by several immune cells (notably CD4 T cells in the tumour and spleen), which promotes an immunosuppressive TME. Lastly, we identified a highly immunosuppressive CD39 + regulatory T cell population (ICOS + , CTLA4 + , Ki67 + ) as a potential biomarker of the risk of EPO‐induced tumour progression. EPO displays pleiotropic immunosuppressive functions and enhances mammary tumour progression in mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, CDApyraseErythropoietinTriple Negative Breast NeoplasmsTumor MicroenvironmentAnimalsFemaleMiceCD4-Positive T-LymphocytesCell Line, TumorDisease Models, AnimalDisease ProgressionMammary Neoplasms, ExperimentalMice, Inbred BALB CT-Lymphocytes, Regulatory

Stichwörter der Autor:innen

T cellexhaustionflow cytometryrodenttumour immunology

Substanzen

Antigens, CDApyraseCD39 antigenErythropoietinEpo protein, mouse

Autor:innen und Institutionen

  • Université Paris Cité, CNRS, INSERM, UTCBS, Unité des Technologies Chimiques et Biologiques pour la Santé, Paris, France.
  • Clinical Immunology Laboratory, Groupe Hospitalier Universitaire Paris-Sud, Hôpital Kremlin-Bicêtre, Assistance Publique-Hôpitaux de Paris, Le-Kremlin-Bicêtre, France.
  • GenoSplice Technology, Paris, France.

ORCID-Profile: Stéphanie Bessoles

Förderung

  • Groupement des Entreprises Françaises dans la lutte contre le Cancer
  • Ligue Contre le Cancer

Zitieren

APA

Bessoles, S., Chiron, A., Sarrabayrouse, G., De La Grange, P., Abina, A. M., & Hacein-Bey-Abina, S. (2024). Erythropoietin induces tumour progression and CD39 expression on immune cells in a preclinical model of triple‐negative breast cancer. Immunology. https://doi.org/10.1111/imm.13832

Vancouver

Bessoles S, Chiron A, Sarrabayrouse G, De La Grange P, Abina AM, Hacein-Bey-Abina S. Erythropoietin induces tumour progression and CD39 expression on immune cells in a preclinical model of triple‐negative breast cancer. Immunology. 2024. doi:10.1111/imm.13832

BibTeX
@article{Bessoles2024,
  author = {Bessoles, Stéphanie and Chiron, Andrada and Sarrabayrouse, Guillaume and De La Grange, Pierre and Abina, Amine M and Hacein-Bey-Abina, Salima},
  title = {Erythropoietin induces tumour progression and CD39 expression on immune cells in a preclinical model of triple‐negative breast cancer},
  journal = {Immunology},
  year = {2024},
  doi = {10.1111/imm.13832}
}
Kostenlos starten →